Abstracts Archive - Page 996 of 2607 - ACR Meeting Abstracts

Abstract Number: 838 • 2019 ACR/ARP Annual Meeting
Are PROMIS Measures Associated with Minimal Disease Activity in Psoriatic Arthritis?
Juliette Yedimenko¹, Yuxuan Jin ², Alexis Ogdie ³, Jessica Walsh ⁴, Jose Scher ⁵, Soumya Reddy ⁶ and M. Elaine Husni ¹, ¹Department of Rheumatologic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, ²Quantitative Health Science, Cleveland Clinic, Cleveland, OH, ³Department of Medicine and Rheumatology and Department of Epidemiology and Biostatistics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, ⁴Division of Rheumatology, University of Utah, Salt Lake City, UT, ⁵Division of Rheumatology, New York University School of Medicine and NYU Langone Orthopedic Hospital, New York, NY, ⁶Division of Rheumatology, New York University School of Medicine, New York, NY
Background/Purpose: Patient-reported outcomes (PROs) are an important part of clinical decision making and are frequently used in combination with objective measures of disease activity and…
Abstract Number: 839 • 2019 ACR/ARP Annual Meeting
Disease Activity, Cytokine Profiles, and the Risk of Incident Diabetes in Rheumatoid Arthritis
Joshua Baker¹, Bryant England ², Michael George ³, Grant Cannon ⁴ and Ted Mikuls ⁵, ¹University of Pennsylvania, Philadelphia, PA, ²VA Nebraska-Western IA Health Care System & University of Nebraska Medical Center, Omaha, ³University of Pennsylvania, Philadelphia, ⁴Salt Lake City VA Medical Center and Univeristy of Utah, Salt Lake City, UT, ⁵VA Nebraska-Western IA Health Care System & University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Rheumatoid arthritis is associated with a higher risk of diabetes mellitus (DM) and cardiovascular disease. While disproportional obesity and visceral fat accumulation may contribute…
Abstract Number: 840 • 2019 ACR/ARP Annual Meeting
Trajectory of Multimorbidity in Rheumatoid Arthritis in a U.S. Commercial Insurance Claims Database from 2006-2015
Bryant England¹, Punyasha Roul ², Fang Yu ², Harlan Sayles ², Kaleb Michaud ², Fenglong Xie ³, Jeffrey Curtis ⁴ and Ted Mikuls ⁵, ¹VA Nebraska-Western IA Health Care System & University of Nebraska Medical Center, Omaha, ²University of Nebraska Medical Center, Omaha, NE, ³University of Alabama at Birmingham, Birmingham, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵VA Nebraska-Western IA Health Care System & University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Multimorbidity, the presence of multiple chronic conditions, predisposes individuals to disability and premature mortality. RA is well known to be associated with select chronic…
Abstract Number: 841 • 2019 ACR/ARP Annual Meeting
Elevation of Anti-Citrullinated Protein Antibodies Prior to Rheumatoid Arthritis Onset and Risks for Developing Chronic Obstructive Pulmonary Disease or Asthma
Alessandra Zaccardelli¹, Xinyi Liu ¹, Julia Ford ¹, Jing Cui ¹, Bing Lu ¹, Su H. Chu ², Peter Schur ¹, Cameron Speyer ¹, Karen Costenbader ¹, William Robinson ³, Jeremy Sokolove ⁴, Elizabeth Karlson ¹, Carlos Camargo ⁵ and Jeffrey Sparks ¹, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ³Stanford University, Stanford, CA, ⁴AbbVie Immunology Clinical Development, Redwood City, ⁵Massachusetts General Hospital, Boston, MA
Background/Purpose: Elevation of anti-citrullinated protein antibodies (ACPA) precedes clinical rheumatoid arthritis (RA) diagnosis by years and may originate at inflamed mucosa, including airways. Damage from…
Abstract Number: 842 • 2019 ACR/ARP Annual Meeting
Mortality Ratio and Risk Factors in CT Confirmed Rheumatoid Arthritis Related Lung Disease: UIP, Pleural Effusion and the Time of Diagnosis of Rheumatoid Arthritis – Lung Disease
Mustafa Ekici ¹, Alper Sarı ², Yusuf Baytar ³, Ertugrul Cagri Bolek ², Berkan Armagan ⁴, Emre Bilgin ², Bayram Farisoğulları ², Omer Karadag ⁵, Ali İhsan Ertenli ², Sedat Kiraz ⁵, Şule Apras Bilgen ⁵, Levent Kilic ⁵, Ali Akdoğan ², Gamze durhan ³, Macit arıyürek ³ and Umut Kalyoncu⁶, ¹Hacettepe University, Faculty of Medicine, Department of Internal Medicine, Ankara, Turkey, ²Hacettepe University Vasculitis Centre, Ankara, Turkey, Ankara, Turkey, ³Hacettepe University, Faculty of Medicine, Department of Radiology, Ankara, Turkey, ⁴Department of Internal Medicine, Hacettepe University, Faculty of Medicine, Ankara, Turkey., Ankara, Turkey, ⁵Hacettepe University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, ankara, Turkey, ⁶Hacettepe University Department of Rheumatology, Ankara, Turkey
Background/Purpose: The frequency of pulmonary involvement in rheumatoid arthritis varies between 7-35%. The most important cause of death in RA patients is lung disease in…
Abstract Number: 843 • 2019 ACR/ARP Annual Meeting
High Lung Attenuation Measured with Quantitative Densitometry as a Surrogate Marker for Interstitial Lung Disease in RA: Association with Anti-CCP, Smoking, and Absence of Shared Epitope
Michail Alevizos¹, Sonye Danoff ², Dimitrios Pappas ¹, David Lederer ³, Cheilonda Johnson ⁴, Elana Bernstein ⁵, Joan Bathon ⁵ and Jon Giles ⁵, ¹Division of Rheumatology, Columbia University, New York, ²Division of Pulmonary & Critical Care Medicine, Johns Hopkins University, Baltimore, ³Division of Pulmonary & Critical Care Medicine, Columbia University, New York, ⁴Division of Pulmonary & Critical Care Medicine, University of Pennsylvania, Philadelphia, ⁵Division of Rheumatology, Columbia University, New York, NY
Background/Purpose: Risk factors for rheumatoid arthritis-associated interstitial lung disease (RA-ILD), a significant cause of morbidity and mortality, are poorly understood. RA-ILD detection is limited by…
Abstract Number: 844 • 2019 ACR/ARP Annual Meeting
Impact of Glucocorticoid Tapering on Markers of Bone Metabolism in Patients with Rheumatoid Arthritis Who Achieved Low Disease Activity or Remission on Tocilizumab: Exploratory Analysis from a Randomized Controlled Trial
Frank Buttgereit¹, Gerd Burmester ², J. Michael Nebesky ³, Jenny Devenport ³, Marc Y. Donath ⁴ and Markus R. John ³, ¹Charité-Universitätsmedizin Berlin, Berlin, Germany, ²Charité—University Medicine Berlin, Berlin, Germany, ³F. Hoffmann-La Roche, Basel, Switzerland, ⁴University Hospital Basel, Basel, Switzerland
Background/Purpose: Glucocorticoids (GCs) directly impact bone metabolism via increased bone resorption and inhibited bone formation1; hence, systemic fracture risk increases with daily and cumulative GC…
Abstract Number: 845 • 2019 ACR/ARP Annual Meeting
Comparison of Rituximab-Associated Hypogammaglobulinemia Rates in Patients with Systemic Rheumatologic Conditions
Stefanie Wade¹ and Vasileios Kyttaris ¹, ¹Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
Background/Purpose: Rituximab (RTX) is used in a wide variety of rheumatic disease. Emerging guidelines suggest measuring immunoglobulins (Ig) at pre-treatment screening and prior to repeat…
Abstract Number: 846 • 2019 ACR/ARP Annual Meeting
MACE and VTE Across Multiple Upadacitinib Studies in Rheumatoid Arthritis: Integrated Analysis from the SELECT Phase 3 Clinical Program
Ernest Choy¹, Iain McInnes ², John Cush ³, Jacob Aelion ⁴, Ying Zhang ⁵, Nasser Khan ⁶, Jianzhong Liu ⁶, Heidi Camp ⁷, Sebastian Meerwein ⁸, William Rigby ⁹ and Alexander Cohen ¹⁰, ¹Cardiff University School of Medicine, Cardiff, United Kingdom, ²Institute of Infection, Immunity & Inflammation, University of Glasgow, Glasgow, United Kingdom, ³5Baylor University Medical Center, Dallas, ⁴Arthritis Clinic PLLC, Jackson, ⁵AbbVie Inc., North Chicago, IL, USA, North Chicago, IL, ⁶Abbvie Inc, North Chicago, IL, ⁷AbbVie Inc., North Chicago, IL, ⁸AbbVie GmbH Co. KG, Ludwigshafen, Germany, Wiesbaden, Germany, ⁹Dartmouth-Hitchcock Medical Center, Lebanon, ¹⁰Guy’s and St Thomas’ NHS FT Hospitals, King’s College London, London, United Kingdom
Background/Purpose: Patients (pts) with RA have an approximate 2-fold increased risk of cardiovascular (CV) morbidity and mortality and of venous thromboembolic events (VTE)1,2. Among RA…
Abstract Number: 847 • 2019 ACR/ARP Annual Meeting
Safety Profile of Baricitinib for the Treatment of Rheumatoid Arthritis up to 7 Years: An Updated Integrated Safety Analysis
Mark Genovese¹, Josef Smolen ², Tsutomu Takeuchi ³, Gerd Burmester ⁴, Dennis Brinker ⁵, Terence Rooney ⁵, Jinglin Zhong ⁶, Daojun Mo ⁵, Chadi Saifan ⁵, Anabela Cardoso ⁵, Maher Issa ⁵, Wen-Shuo Wu ⁵ and Kevin Winthrop ⁷, ¹Stanford University, Stanford, CA, ²Medical University of Vienna, Vienna, Austria, ³Keio University School of Medicine, Tokyo, Japan, ⁴Charité—University Medicine Berlin, Berlin, Germany, ⁵Eli Lilly and Company, Indianapolis, IN, ⁶IQVIA, Morrisville, NC, ⁷Oregon Health and Science University, Portland, OR
Background/Purpose: Baricitinib (bari), an oral, selective inhibitor of Janus kinase (JAK) 1 and 2, is used to treat moderately to severely active RA in adults.…
Abstract Number: 848 • 2019 ACR/ARP Annual Meeting
Risk of Serious Infection with Long-Term Use of Low-Dose Glucocorticoids in Patients with Rheumatoid Arthritis
Michael George¹, Joshua Baker ², Kevin Winthrop ³, Qufei Wu ², Lang Chen ⁴, Fenglong Xie ⁵, Huifeng Yun ⁴ and Jeffrey Curtis ⁴, ¹University of Pennsylvania, Philadelphia, ²University of Pennsylvania, Philadelphia, PA, ³Oregon Health and Science University, Portland, OR, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵University of Alabama at Birmingham, Birmingham
Background/Purpose: As many as 30-40% of patients with RA remain on long term glucocorticoids. Infection risk with higher dose glucocorticoids is well known, but evidence…
Abstract Number: 849 • 2019 ACR/ARP Annual Meeting
Risk of Malignancies Associated with Biologics in Rheumatoid Arthritis: Analysis of a National Claim Database
Raphaèle Seror¹, Alexandre Lafourcade ², yann De Rycke ², Bruno Fautrel ³, Xavier Mariette ⁴ and Florence Tubach ⁵, ¹Université Paris Sud, Hôpitaux Universitaires Paris-Sud, AP-HP, INSERM UMR 1184, Le Kremlin-Bicêtre, France, ²Biostatistics, Public Health and Medical Information department, Pitié-Salpêtrière Hospital, AP-HP, Paris, France, Paris, France, ³Pitié-Salpêtrière Hospital, Department of Rheumatology, AP-HP, Sorbonne University, UPMC university, Paris, Ile-de-France, France, ⁴Center for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique – Hôpitaux de Paris, Hôpitaux Universitaires Paris-Sud, Le Kremlin-Bicêtre, Université Paris Sud, INSERM, Paris, France, ⁵Pitié Salpétrière University-Hospital, Paris, Ile-de-France, France
Background/Purpose: Our objectives were to estimate and compare the incidence rate of malignancies between biologic and csDMARD-treated RA patients.Methods: We conducted an historical cohort study…
Abstract Number: 850 • 2019 ACR/ARP Annual Meeting
Safety of Synthetic and Biological DMARDs: A Systematic Literature Review Informing the 2019 Update of the EULAR Recommendations for Management of Rheumatoid Arthritis
Alexandre Sepriano¹, Andreas Kerschbaumer ², Josef Smolen ², Désirée van der Heijde ¹, Maxime Dougados ³, Ronald F Van Vollenhoven ⁴, Iain McInnes ⁵, Johannes Bijlsma ⁶, Gerd Burmester ⁷, Maarten de Wit ⁸, Louise Falzon ⁹ and Robert B.M. Landewé ¹⁰, ¹Leiden University Medical Center, Leiden, Netherlands, ²Medical University of Vienna, Vienna, Austria, ³Cochin Hospital, Paris, France, ⁴Amsterdam Rheumatology & Immunology Center, Amsterdam, Netherlands, ⁵College of Medical Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom, ⁶UMC Utrecht, Department of Rheumatology & Clinical Immunology, Utrecht, The Netherlands, Utrecht, Netherlands, ⁷Charité—University Medicine Berlin, Berlin, Germany, ⁸Department of Medical Humanities, Amsterdam Public Health (APH), Amsterdam University Medical Centre, Amsterdam, Netherlands, ⁹Northwell Health, New York, ¹⁰Amsterdam University Medical Center, Amsterdam, Netherlands
Background/Purpose: To assess the most recent safety-data of synthetic (s) and biological (b)DMARDs to inform the 2019 update of the EULAR recommendations for the management…
Abstract Number: 851 • 2019 ACR/ARP Annual Meeting
Association Between Bone Marrow Edema and Structural Progression in the Same Quadrant in Axial Spondyloarthritis – 5-year Data from the DESIR Cohort
Santiago Rodrigues-Manica¹, Alexandre Sepriano ², Sofia Ramiro ³, Robert B.M. Landewé ⁴, Pascal Claudepierre ⁵, Anna Molto ⁶, Maxime Dougados ⁷, Miranda van Lunteren ² and Désirée van der Heijde ², ¹CEDOC, NOVA-Medical School | Hospital Egas Moniz, CHLO, Lisbon, Lisbon, Portugal, ²Leiden University Medical Center, Leiden, Netherlands, ³Leiden University Medical Center and Zuyderland Medical Centre, Leiden, Netherlands, ⁴Amsterdam University Medical Center, Amsterdam, Netherlands, ⁵Rheumatology, CHU Henri Mondor Créteil, Paris, France, ⁶Paris Descartes University, Medicine Faculty; APHP, Rheumatology, Hôpital Cochin, Hôpitaux de Paris, Paris, Paris, France, ⁷Cochin Hospital, Paris, France
Background/Purpose: The overall presence of inflammation in the MRI-SIJ is associated with overall 5-year radiographic damage in patients with axSpA. But we do not know…
Abstract Number: 852 • 2019 ACR/ARP Annual Meeting
Ileal but Not Colonic Inflammation Is Linked to Fatty Lesions on MRI of the Sacroiliac Joints in Spondyloarthritis Patients
Ann-Sophie De Craemer¹, Manouk de Hooge ¹, Thomas Renson ¹, Liselotte Deroo ¹, Triana Lobaton Ortega ², Anne Hoorens ³, Philippe Carron ¹, Filip Van den Bosch ¹ and Dirk Elewaut ¹, ¹Ghent University Hospital, Ghent, Belgium, ²Ghent University Hospital, Gent, Oost-Vlaanderen, Belgium, ³Ghent University Hospital, Gent
Background/Purpose: Gut and joint inflammation in spondyloarthritis (SpA) are closely intertwined. About 50% of axial SpA patients display microscopic signs of inflammation in ileum and/or…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].